Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D08FAB
|
||||
Former ID |
DNC005714
|
||||
Drug Name |
3-(naphthalen-2-yl)pyridine
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [529667] | ||
Structure |
Download2D MOL |
||||
Formula |
C15H11N
|
||||
Canonical SMILES |
C1=CC=C2C=C(C=CC2=C1)C3=CN=CC=C3
|
||||
InChI |
1S/C15H11N/c1-2-5-13-10-14(8-7-12(13)4-1)15-6-3-9-16-11-15/h1-11H
|
||||
InChIKey |
JVWGLICJXUMGHN-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Cytochrome P450 19 | Target Info | Inhibitor | [529834] | |
Cytochrome P450 11B1, mitochondrial | Target Info | Inhibitor | [529667] | ||
NetPath Pathway | FSH Signaling Pathway | ||||
PANTHER Pathway | Androgen/estrogene/progesterone biosynthesis | ||||
PathWhiz Pathway | Androgen and Estrogen MetabolismPW000141:Steroidogenesis | ||||
WikiPathways | Metapathway biotransformation | ||||
Tryptophan metabolism | |||||
Oxidation by Cytochrome P450 | |||||
Ovarian Infertility Genes | |||||
Metabolism of steroid hormones and vitamin D | |||||
FSH signaling pathway | |||||
Integrated Breast Cancer Pathway | |||||
Phase 1 - Functionalization of compoundsWP702:Metapathway biotransformation | |||||
Corticotropin-releasing hormone | |||||
References | |||||
Ref 529667 | J Med Chem. 2008 Oct 9;51(19):6138-49. Epub 2008 Sep 3.Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. | ||||
Ref 529834 | J Med Chem. 2008 Dec 25;51(24):8077-87.In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.